Fiche centre
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda — United States
Essais liés4clinical trials
VilleBethesdalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT00001669
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| rhIGF-1 (CEP-151) | SEP | Phase 2 | NCT00001669 | A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients | COMPLETED |
| Herpes Virus-6 and Epilepsy | Épilepsie | À vérifier | NCT00085683 | Herpes Virus-6 and Epilepsy | COMPLETED |
| KW-6002 | Parkinson | Phase 2 | NCT00006337 | KW-6002 to Treat Parkinson's Disease | COMPLETED |
| Effects of Antiepileptic Drugs on Brain Excitability | Épilepsie | À vérifier | NCT00054990 | Effects of Antiepileptic Drugs on Brain Excitability | COMPLETED |